Home » News » Drug Sponsors » Takeda invests in Fate Therapeutics

Takeda invests in Fate Therapeutics

Tuesday, May 10, 2011

Japan-based Takeda has made a strategic investment in the U.S.-based Fate Therapeutics, a privately-held firm that specializes in stem cell research, according to Pharma Times.

The investment has been made via the Japanese drugmaker’s corporate venture arm, Takeda Ventures, and is designed to expand Takeda’s portfolio in regenerative medicine.

Fate’s first therapeutic candidate is now in phase Ib studies in hematopoietic reconstitution in patients with malignancies such as leukemia and lymphoma.

Takeda says its new partner utilizes “the most advanced biologics and reprogramming technologies for identifying promising points of therapeutic intervention.” Fate has secured backing from venture firms and the investment arms of Astellas and Genzyme.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!